Cost-Effectiveness of Rituximab Maintenance Treatment Versus Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed Follicular Lymphoma (FL).

Leppä, Sirpa; Linna, Miika; Nyman, Heidi; Taimela, Eeva

doi:10.1182/blood.v108.11.3337.3337

Public

Cost-Effectiveness of Rituximab Maintenance Treatment Versus Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed Follicular Lymphoma (FL).

Published in Blood • Nov 16, 2006

Authors:

Sirpa Leppä

Miika Linna

Heidi Nyman

Abstract

Abstract PURPOSE: High dose chemotherapy followed by ASCT is commonly used in responding patients with FL as consolidation treatment in first relapse. Recently, rituximab maintenance treatment has shown to improve both progression free (PFS) and overall survival (OS) in the same patient population. ...

Subject

Rituximab

Medicine

Maintenance therapy

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!